Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MV140 confirmatory placebo-controlled trial in women with recurrent uncomplicated urinary tract infection
2025-524377-16-00Phase 3Authorised
- Sponsor
- Inmunotek
- Start
- May 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in urinary tract infection (UTI) and cystitis comparing MV140 with Placebo for MV140 (2 arms). Primary endpoint: Number of new urinary tract infection episodes over 15 months. Planned start May 2026; status: authorised.
02
Drugs
MV140
03
Conditions
urinary tract infection (UTI)cystitis
Beyond the preview
Go deeper on 2025-524377-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524377-16-00.